# Cue Reactivity Modulation in MSM with Methamphetamine Use Disorder

> **NIH NIH R61** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $415,322

## Abstract

PROJECT SUMMARY
In the midst of the opioid epidemic, methamphetamine use is emerging as the next substance use crisis with
disproportionately increasing prevalence in men who have sex with men (MSM), high relapse rates and no
FDA-approved treatments for individuals with methamphetamine use disorder (MUD). One of the major
contributors to relapse is the enhanced motivated arousal (cue-reactivity) to drug-related cues, even after
protracted abstinence that leads to an increase in craving and drug-seeking. Although cue-reactivity is studied
widely in other substance use disorders, its study is scarce in MUD and non-existent in MSM with MUD,
creating a critical gap in knowledge needed for unbiased assessment of disease severity and treatment
outcomes in this rapidly growing clinical population. Therefore, in this bi-phased study, we propose to first
identify a psychophysiological marker of methamphetamine cue-reactivity and its incubation with abstinence
from methamphetamine use and examine group-differences between MSM and non-MSM MUD.
Subsequently, in the second phase we propose to longitudinally assess incubation of cue-reactivity, its
reduction with cognitive reappraisal (CR; a self-regulation technique) and examine the impact of CR on clinical
outcomes in MSM with MUD. In light of preliminary findings from our group, we hypothesize that LPP, an
electroencephalography-derived marker of drug cue-reactivity, will track the incubation of methamphetamine
cue-reactivity and its CR-mediated reduction, which in turn will be associated with improved clinical outcomes
in MSM with MUD. In the R61 phase, we will cross-sectionally compare the LPP-assessed cue-reactivity
between currently using (Group 1) and abstinent (1-3 months; Group 2) individuals with MUD (50% MSM in
each group, matched on HIV status), and examine in-task changes in cue-reactivity with CR technique. In the
R33 phase, we will assign a cohort of MUD to either the CR+ (Cognitive Reappraisal training) or the CR- (no
Cognitive Reappraisal training) group (all MSM, matched on HIV status), and cue-reactivity will be assessed
longitudinally at <2 weeks, 2 months, to 3 months after abstinence initiation. Successful completion of these
aims will identify an EEG-based, objective, and clinically useful marker of methamphetamine cue-reactivity,
and will delineate the impact of CR on methamphetamine cue-reactivity in relation to treatment response in
MSM with MUD. This work will be the beginning of mechanistic research into the role of incubation of
methamphetamine cue-reactivity and its reduction as a reliable and clinically meaningful outcome measure,
establishing an empirical foundation to develop an intervention for MUD and possibly in other addictions.

## Key facts

- **NIH application ID:** 10931651
- **Project number:** 5R61DA056779-02
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Muhammad Adeel Parvaz
- **Activity code:** R61 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $415,322
- **Award type:** 5
- **Project period:** 2023-09-30 → 2026-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10931651

## Citation

> US National Institutes of Health, RePORTER application 10931651, Cue Reactivity Modulation in MSM with Methamphetamine Use Disorder (5R61DA056779-02). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10931651. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*